Mitsubishi UFJ Asset Management Co. Ltd. Invests $26.41 Million in Insulet Corporation $PODD

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 173,480 shares of the medical instruments supplier’s stock, valued at approximately $26,412,000.

Other large investors have also made changes to their positions in the company. OneDigital Investment Advisors LLC bought a new position in Insulet in the second quarter worth $6,741,000. Plato Investment Management Ltd acquired a new stake in Insulet during the second quarter worth $357,000. Global Retirement Partners LLC bought a new stake in Insulet in the 2nd quarter valued at $86,000. Bank of New York Mellon Corp bought a new stake in Insulet in the 2nd quarter valued at $60,615,000. Finally, Focus Partners Advisor Solutions LLC acquired a new position in shares of Insulet in the 2nd quarter valued at $640,000.

Insulet Stock Performance

Shares of Insulet stock opened at $146.87 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The firm has a market cap of $10.19 billion, a P/E ratio of 27.45, a P/E/G ratio of 1.19 and a beta of 1.10. The firm has a 50 day simple moving average of $154.70 and a 200 day simple moving average of $185.07. Insulet Corporation has a fifty-two week low of $126.40 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same quarter last year, the firm earned $1.17 EPS. The company’s revenue for the quarter was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Sell-side analysts predict that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PODD. Truist Financial restated a “hold” rating and set a $153.00 price target (down from $210.00) on shares of Insulet in a research note on Wednesday, August 5th. Wells Fargo & Company cut Insulet from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $255.00 to $144.00 in a report on Wednesday, August 5th. Robert W. Baird set a $175.00 target price on Insulet in a research report on Thursday, August 6th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $205.00 price target on shares of Insulet in a research note on Wednesday, May 27th. Finally, BTIG Research cut Insulet from a “buy” rating to a “neutral” rating in a research report on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $195.40.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Negative Sentiment: Multiple law firms announced or promoted a securities class action against Insulet and certain executives. The complaints allege that the company made materially false or misleading statements about manufacturing controls, product quality, and the safety and reliability of Omnipod devices. The allegations have not been proven in court. Pomerantz class action announcement
• Negative Sentiment: The investor notices link the case to two Omnipod medical-device corrections and claim that related disclosures contributed to a substantial decline in Insulet’s stock. One notice cited a move from $236.07 to $146.01 across the alleged corrective disclosures, or losses exceeding $90 per share for some investors. SueWallSt investor notice
• Negative Sentiment: The legal overhang intensified as several firms—including Robbins Geller, Faruqi & Faruqi, Rosen, Bronstein Gewirtz & Grossman, Bernstein Liebhard, Glancy Prongay, Robbins LLP, Levi & Korsinsky, and Portnoy—urged affected shareholders to seek lead-plaintiff status or evaluate potential recovery. The deadline to move for lead-plaintiff appointment is August 31, 2026. Robbins Geller deadline announcement

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were acquired at an average price of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.36% of the stock is currently owned by corporate insiders.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.